Unveiling the Secret Life of FBLN7: A Key Player in Adipose Tissue Fibrosis
Fibrosis, a condition marked by excessive extracellular matrix (ECM) buildup, is a significant contributor to the dysfunction of adipose tissue (AT) and insulin resistance in obesity. Recent studies have pointed to adipogenic stem and precursor cells (ASPCs) as a primary source of ECM proteins, capable of triggering AT fibrosis. In this groundbreaking research, we utilized single-cell RNA-seq to uncover a distinct group of ASPCs intimately linked to ECM function.
But here's the intriguing part: Within this subset, we discovered a significant increase in the expression of Fibulin-7 (FBLN7), a secreted glycoprotein, in obese mice. This finding is not isolated to mice; in humans, elevated FBLN7 levels were observed in visceral fat of obese individuals and were linked to clinical metabolic traits. And this is where it gets even more fascinating—when these ASPCs were specifically manipulated to lack FBLN7, the mice showed reduced AT fibrosis-inflammation and improved metabolic health when exposed to a calorie-rich diet. Conversely, boosting FBLN7 expression intensified fibrogenic responses.
The underlying mechanism involves FBLN7's interaction with thrombospondin-1 (TSP1) through its EGF-like calcium-binding domain, which stabilizes TSP1. This stabilization process then activates latent TGF-β, triggering TGFBR1/Smad signaling pathways. We also engineered an anti-FBLN7 neutralizing antibody, which remarkably reduced diet-induced AT fibrosis. These findings strongly imply that FBLN7, originating from ASPCs, plays a pivotal role in AT fibrosis and could be a promising therapeutic target.
A Controversial Twist: While the study suggests FBLN7 as a potential therapeutic target, it also raises questions about the broader implications of manipulating this protein. Could targeting FBLN7 have unforeseen consequences on other physiological processes? The intricate balance of the body's systems means that interventions must be approached with caution.
What are your thoughts on this research? Do you think FBLN7 is a viable therapeutic target for obesity-related conditions, or should we proceed with caution? Share your insights below!
